NRX Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
About NRX Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops and distributes novel therapeutics for central nervous system disorders. Through its operating subsidiary, NeuroRx, Inc., the company focuses on treatments for conditions such as suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. Its lead drug candidates include preservative-free ketamine formulations (NRX-100 and KETAFREE™) and NRX-101, an oral combination therapy targeting neuroplasticity pathways. In addition, NRx operates a medical services segment through its majority-owned subsidiary, HOPE Therapeutics, Inc., which delivers interventional psychiatric care using neuromodulatory devices, neuroplastic drugs, digital therapeutics, and hyperbaric therapy. Its primary end customers are patients suffering from severe psychiatric and neurological conditions.
The company operates five clinical facilities in Florida, with clinics in Naples, Fort Myers, Sarasota, and West Palm Beach, and is developing additional sites in Massachusetts and Colorado. As of December 31, 2025, NRx employed approximately 29 full-time personnel. The provided text does not disclose the location of the company's headquarters.
Summary of the business section of NRX Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NRX Pharmaceuticals, Inc.
- Founded
- 2018
- Headquarters
- Wilmington, DE
- Address
- 1201 Orange Street, Suite 600 19801
- Phone
- (484) 254-6134
- Employees
- 29, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company P.A., Los Angeles, CA
Stock & identifiers
- Ticker
- NRXP
- Exchange
- Nasdaq
- IPO date
- Nov 21, 2017
- Shares outstanding
- 43M, Aug 14, 2026
- Public float
- $57.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Apr 2, 2024; 1-for-10 reverse, Mar 24, 2024; 49-for-4, Aug 16, 2021
- SEC CIK
- 1719406
- CUSIP
- 629444209
- ISIN
- US6294442099
- LEI
- 5493003FN4CLS0670T77
- EIN
- 82-2844431
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan C. Javitt | Chairman and Chief Scientist, Director | 1,516,834 |
| Joseph Michael Casper | Chief Operating Officer | – |
| Michael S. Abrams | Chief Financial Officer | – |
| Patrick John Flynn | Director | 39,459 |
| Chaim Hurvitz | Director | 2,214,793 |
| Dennis McBride | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 PEO1 | $789.58K | $789.58K | $1.22M | $46 | – |
| FY2024 PEO2 | $0 | $0 | $1.22M | $46 | – |
| FY2024 PEO3 | – | $393.75K | $1.22M | $46 | – |
| FY2023 PEO1 | $500.00K | -$150.00K | $857.77K | $19 | – |
| FY2023 PEO2 | $0 | $0 | $857.77K | $19 | – |
| FY2023 PEO3 | – | $0 | $857.77K | $19 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had approximately 29 full-time employees.”
Corporate history
Events identified from SEC filings